MACS Click Synthesis
The MACS technology represents a guarantee of high purity, high quality, and zero contamination.
In trauma care and battlefield medicine, rapid hemostasis often determines life or death. Yet existing solutions suffer from limitations: poor absorbability, storage issues, lack of antimicrobial action, and high costs.
Inspired by the need for robust, ready-to-use field solutions, we repurposed our MACS™ platform—originally developed for anticancer and antibiotic applications—to create an advanced hemostatic material optimized for real-world emergencies.
Rapid
Safe
Scalable
RealSeal transforms trauma care with speed, safety, and scale.
The MACS technology represents a guarantee of high purity, high quality, and zero contamination.
The only clean, scalable platform for high-purity medical-grade amino acid-metal chelates.
30–40% faster clotting, 60–70% less blood loss vs competing products
Over eight amino acid–metal complexes have already been successfully synthesized, forming a versatile platform suitable for diverse trauma applications including burn injuries, ulcerative wounds, and post-operative care.
MACS Hemostat | Chitosan / Zeolite | |
---|---|---|
Technology Mechanism | Metal Amino Click Synthesis (MACS) technology | Physical expansion (chitosan or kaolin-based) |
Hemostasis Efficiency | Stops bleeding within 60 seconds (animal trials) | 2–3 minutes to stop bleeding |
Antibacterial Function | Yes – integrated metal-based antimicrobial action | No antibacterial function |
Storage & Portability | Powder form, long shelf life at room temperature | Limited – some require special packaging or temperature |
Ease of Use | Directly pour into wound, no pre-treatment needed | Requires preparation or application pressure |
Biocompatibility | High – amino acid-based, naturally absorbable | Moderate – some users may have sensitivity |
Scalability of Production | High – clean water-based synthesis, low-cost process | Medium – multi-step or animal-derived raw materials |
Customization Potential | Yes – modular design supports varied clinical formulations | Low – fixed material mechanism |
Cost Efficiency | Lower production cost, scalable formulation | Higher cost due to material constraints |
Regulatory Path Potential | Designed for easy clinical adoption and regulatory approval | Existing products approved but with limitations |
Clots up to 81% faster
Forms stronger, more stable clots
Nutrient-safe and cell-absorbable
Integrated metal-based protection
Naturally breaks down after use
Lower production cost, scalable supply
With 8+ amino acid–metal complexes already synthesized and validated, the MACS platform serves as a versatile modular system for developing next-generation hemostatic and wound care materials.
By leveraging its scalable, clean synthesis process, MACS technology enables rapid formulation, customization, and commercial readiness for diverse clinical use cases.
The MACS platform is ready for broader clinical validation and commercialization.
Let's co-develop the future of trauma care.
We welcome collaboration in clinical trials, licensing, or joint development.